Samuel Backenroth, Chief Financial Officer at Ohr Pharmaceutical Inc (OHRP), bought 2,511 shares at $3.23 ($8K) on 2016-05-23, disclosed to the SEC on 2016-05-24.
Open-market purchase of $8k OHRP by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.11 | 33 | $103 | 1.3% |
| 2 | $3.12 | 163 | $509 | 6.4% |
| 3 | $3.13 | 11 | $34 | 0.4% |
| 4 | $3.13 | 97 | $304 | 3.8% |
| 5 | $3.13 | 11 | $34 | 0.4% |
| 6 | $3.14 | 43 |
| $135 |
| 1.7% |
| 7 | $3.15 | 184 | $580 | 7.3% |
| 8 | $3.16 | 379 | $1K | 15.0% |
| 9 | $3.17 | 834 | $3K | 33.2% |
| 10 | $3.18 | 192 | $611 | 7.7% |
| 11 | $3.19 | 152 | $485 | 6.1% |
| 12 | $3.20 | 54 | $173 | 2.2% |
| 13 | $3.21 | 184 | $591 | 7.4% |
| 14 | $3.22 | 11 | $35 | 0.4% |
| 15 | $3.23 | 163 | $526 | 6.6% |
| Total | $3.17 avg | 2,511 | $8K | 100% |
| Filing → |
| OHRP | BUY | 2016-06-21 | $7K | — | Filing → |
| OHRP | BUY | 2015-02-10 | $10K | — | Filing → |